Results 41 to 50 of about 41,330 (277)

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice [PDF]

Терапевтический архив, 2018
Objective: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice. Materials and methods.The article contains long-term results analysis of ATR application under real clinical ...
V V PTUSHKIN, O Yu VINOGRADOVA, M M PANKRASHKINA, M V CHERNIKOV, E G ARSHANSKAYA, N E TKACHENKO   +5 more
doaj   +1 more source

Newly Diagnosed Primary Immune Thrombocytopenia in Children: Which Guideline to Adhere?

Scripta Score Scientific Medical Journal, 2021
Background: Immune thrombocytopenia purpura (ITP) is an autoimmune disorder of bleeding which is defined as having thrombocytopenia (platelet count below 100.000/µL).
Cipta Mahendra
doaj   +1 more source

Rilzabrutinib for the Treatment of Immune Thrombocytopenia. [PDF]

Eur J Haematol
ABSTRACT Advancements in the understanding of ITP pathogenesis have led to significant improvements in disease management through the use of both traditional immunosuppressive strategies and novel targeted therapies. However, a subset of patients remains refractory to treatment or achieves only transient benefits, underscoring the need for alternative ...
Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Caridà G, Lucia E, Olivito V, Manicardi V, Amodio N, Neri A, Morabito F, Gentile M.   +12 more
europepmc   +2 more sources

Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia

Open Medicine, 2016
Primary immune thrombocytopenia (ITP) is a complex autoimmune disorder in which the patient’s immune system reacts with platelet autoantigens resulting in immune-mediated platelet destruction and/or suppression of platelet production. Corticosteroids can
Liu Xin-guang, Hou Ming
doaj   +1 more source

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists

Platelets, 2020
MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of gene expression. Dysregulated expression of several miRNAs has been found in primary immune thrombocytopenia (ITP) suggesting that miRNAs are likely involved in the pathogenesis ...
Lamya Garabet, Waleed Ghanima, Anbjørg Rangberg, Raul Teruel-Montoya, Constantino Martinez, Maria Luisa Lozano, Camilla F. Nystrand, James B. Bussel, Per Morten Sandset, Christine M. Jonassen   +9 more
doaj   +1 more source

Endothelial alterations in a canine model of immune thrombocytopenia

Platelets, 2019
Bleeding heterogeneity amongst patients with immune thrombocytopenia (ITP) is poorly understood. Platelets play a role in maintaining endothelial integrity, and variable thrombocytopenia-induced endothelial changes may influence bleeding severity ...
Dana N. LeVine, Rachel E. Cianciolo, Keith E. Linder, Petra Bizikova, Adam J. Birkenheuer, Marjory B. Brooks, Abdelghaffar K. Salous, Shila K. Nordone, Dwight A. Bellinger, Henry Marr, Sam L. Jones, Thomas H. Fischer, Yu Deng, Marshall Mazepa, Nigel S. Key   +14 more
doaj   +1 more source

Treatment of immune thrombocytopenia (ITP) secondary to malignancy: a systematic review

Platelets, 2022
Immune thrombocytopenia (ITP) can be associated with lymphoproliferative diseases (LPD) or solid tumors. A systematic review of published literature was conducted to evaluate response to treatment of ITP secondary to malignancy.
Gian Marco Podda, Elisa M. Fiorelli, Simone Birocchi, Benedetta Rambaldi, Maria Chiara Di Chio, Giovanni Casazza, Marco Cattaneo   +6 more
doaj   +1 more source

Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study

Platelets, 2023
The emergence of rituximab biosimilars offers the prospect of significant savings to the healthcare system. However, these drugs have never been evaluated for treating immune thrombocytopenia (ITP). This was an observational, matched study.
Arthur Mageau, Bernard Bonnotte, Mikael Ebbo, Antoine Dossier, Lionel Galicier, Odile Souchaud-Debouverie, Corentin Orvain, Mathieu Gerfaud-Valentin, Delphine Gobert, Etienne Riviere, Sylvain Audia, Matthieu Mahevas, Marc Michel, Jean-Francois Viallard, Bertrand Godeau   +14 more
doaj   +1 more source

Numerical and Experimental Study of Flutter in a Realistic Labyrinth Seal

International Journal of Turbomachinery, Propulsion and Power
Labyrinth seals are commonly used in turbomachinery in order to control leakage flows. Flutter is one of the most dangerous potential issues for them, leading to High Cycle Fatigue (HCF) life considerations or even mechanical failure.
Oscar Bermejo, Juan Manuel Gallardo, Adrian Sotillo, Arnau Altuna, Roberto Alonso, Andoni Puente   +5 more
doaj   +1 more source

Report of a ‘consensus’ on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine

Platelets, 2020
Despite the publication in 2009 of a paper on ‘terms and definitions of immune thrombocytopenia’ (ITP), some unresolved issues remain and are reflected by the disagreement in the treatment suggested for primary ITP in adults.
Lorenzo Cirasino, Anna M. Robino, GianMarco Podda, Emmanuel Andrès, Jenny M. Despotovic, Mohsen Elalfy, Andreas Holbro, Tadakazu Kondo, Michele P. Lambert, Sandra R. Loggetto, Keith R. McCrae, Jong Wook Lee, Marco Cattaneo   +12 more
doaj   +1 more source